SCHEMBL18010037

SCHEMBL18010037

O=C(Nc1c(SF)c(SF)c(SF)c(SF)c1SF)c1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.54
PTPN2 P17706 1/20 0.53
PTPN1 P18031 1/20 0.53
PTPN6 P29350 1/20 0.53
PTPN11 Q06124 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 4/20 0.50
TP53 P04637 3/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
ESR2 Q92731 1/20 0.49
GFER P55789 1/20 0.49
CYP1A2 P05177 1/20 0.48
ABCC9 O60706 1/20 0.47
ABCC8 Q09428 1/20 0.47
KCNJ11 Q14654 1/20 0.47
KCNJ8 Q15842 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11150597 0.73 ATM (0.69) RAB9APTPN2PTPN1PTPN6PTPN11
SCHEMBL18010049 0.73 ABCC9 (0.46) RAB9AALDH1A1NPC1ABCC9ABCC8
SCHEMBL1781545 0.72 RAB9A (0.65) RAB9APTPN2PTPN1PTPN6PTPN11
SCHEMBL18010115 0.71 KCNK3 (0.47) RAB9APTPN1PTPN6PTPN11MAPT
SCHEMBL18010128 0.71 CSF1R (0.44) ALDH1A1MAPT
SCHEMBL8702006 0.70 CES2 (0.62) RAB9APTPN2PTPN1PTPN6PTPN11
SCHEMBL2997673 0.70 RAB9A (1.00) RAB9APTPN2PTPN1PTPN6PTPN11
SCHEMBL6633899 0.70 PTPN2 (0.75) RAB9APTPN2PTPN1PTPN6PTPN11
SCHEMBL7743465 0.70 PTPN2 (0.75) RAB9APTPN2PTPN1PTPN6PTPN11
SCHEMBL5691055 0.70 RAB9A (0.63) RAB9ASMN1; SMN2ALDH1A1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682931-B2 Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof UBE INDUSTRIES, LTD. (JP) 2017-06-20 US disclosed
EP-3064489-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF Ube Industries, Ltd. (JP) 2016-09-07 EP disclosed
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF UBE INDUSTRIES, LTD. (JP) 2016-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244407-A1 ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF SLCO1B1, SLCO2B1, SLCO1B3 RAB9A 793/4885PTPN2 214/4885PTPN1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.